Daiichi Sankyo

With ADCs on the rise, drugmakers embrace a new oncology pillar
Pharma Voice
Fri, 06/6/25 - 11:36 am
oncology
ASCO 2025
antibody-drug conjugates
Daiichi Sankyo
AstraZeneca
Enhertu
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
BioPharma Dive
Thu, 06/5/25 - 09:46 am
ASCO 2025
Daiichi Sankyo
antibody-drug conjugates
Hiroyuki Okuzawa
Enhertu
Datroway
At ASCO, Enhertu cements growing role in stomach cancer care
BioPharma Dive
Mon, 06/2/25 - 10:58 am
ASCO 2025
AstraZeneca
Daiichi Sankyo
stomach cancer
Enhertu
Merck and Daiichi Sankyo pull HER3-DXd's FDA filing
Pharmaphorum
Thu, 05/29/25 - 10:33 am
Merck
Daiichi Sankyo
patritumab deruxtecan
HER3-DXd
FDA
Merck KGaA shares phase 3 rare tumor data ahead of showdown with Daiichi and Ono
Fierce Biotech
Wed, 05/28/25 - 09:39 am
Merck KGaA
clinical trials
tenosynovial giant cell tumors
pimicotinib
Daiichi Sankyo
Ono Pharmaceutical
AI tool could help doctors ID breast cancers vulnerable to Enhertu
BioPharma Dive
Thu, 05/22/25 - 09:21 pm
diagnostics
Medtech
breast cancer
artificial intelligence
AstraZeneca
Daiichi Sankyo
Enhertu
New data could move Enhertu into early breast cancer
Pharmaphorum
Wed, 05/7/25 - 11:15 am
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
early breast cancer
breast cancer
AstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancer
Fierce Pharma
Mon, 04/21/25 - 11:12 am
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
clinical trials
Daiichi taps Nosis to deliver RNA therapies beyond the liver
Fierce Biotech
Tue, 03/11/25 - 11:23 am
Daiichi Sankyo
RNA
Nosis Biosciences
drug delivery
artificial intelligence
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial
Clinical Trials Arena
Tue, 03/4/25 - 09:48 am
Daiichi Sankyo
AstraZeneca
Enhertu
clinical trials
gastric cancer
gastroesophageal adenocarcinoma
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
Pharmaceutical Technology
Sun, 02/2/25 - 06:51 pm
Daiichi Sankyo
Hiroyuki Okuzawa
Sunao Manabe
Pharma CEOs
Enhertu, with new FDA OK, set to supplant chemo in HER2-low breast cancer
BioPharma Dive
Tue, 01/28/25 - 10:40 am
AstraZeneca
Daiichi Sankyo
Enhertu
HER2-low breast cancer
FDA
AstraZeneca, Daiichi share data behind Dato-DXd do-over amid 2nd bid for lung cancer approval
Fierce Biotech
Fri, 12/6/24 - 09:51 am
AstraZeneca
Daiichi Sankyo
Dato-DXd
England's NICE turns down cancer drug Enhertu—again—amid pricing stalemate with AZ, Daiichi Sankyo
Fierce Pharma
Tue, 11/19/24 - 07:14 pm
AstraZeneca
Daiichi Sankyo
Enhertu
UK
NICE
AstraZeneca, Daiichi withdraw lung cancer approval application for Enhertu follow-up and try again
Fierce Biotech
Tue, 11/12/24 - 08:44 pm
AstraZeneca
Daiichi Sankyo
lung cancer
FDA
Dato-DXd
Enhertu
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
Pharmaphorum
Fri, 11/8/24 - 11:37 am
Daiichi Sankyo
Alteogen
Enhertu
cancer
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Wed, 10/2/24 - 11:24 am
FDA
Bridge Bio
acoramidis
AstraZeneca
Daiichi Sankyo
Dato-DXd
Vertex Pharmaceuticals
Vanza Triple
PTC Therapeutics
Upstaza
Bristol Myers Squibb
Opdivo
AstraZeneca's experimental drug disappoints in breast cancer survival trial
Reuters
Mon, 09/23/24 - 11:29 am
AstraZeneca
Daiichi Sankyo
clinical trials
breast cancer
Dato-DXd
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns
Medical Marketing and Media
Sun, 09/22/24 - 09:46 pm
Daiichi Sankyo
AstraZeneca
breast cancer
metastatic breast cancer
Enhertu
DTC ads
Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
Fierce Pharma
Thu, 09/19/24 - 11:06 am
artificial intelligence
Bayer
Daiichi Sankyo
Argenx

Pages